Abstract
X-box binding protein-1 (XBP1) is a transcription factor that plays a central role in controlling cellular responses to endoplasmic reticulum (ER) stress. Under stress conditions, the transcriptionally active form of XBP1 is generated by unique splicing of Xbp1 mRNA by the ER-resident protein inositol-requiring enzyme-1 (IRE1α). Genetic deletion of XBP1 has multiple consequences: some resulting from the loss of the transcription factor per se, and others related to compensatory upstream activation of IRE1α. The objective of the current study was to investigate the effects of XBP1 deletion in adult mouse liver and determine to what extent they are direct or indirect. XBP1 was deleted specifically from hepatocytes in adult Xbp1fl/fl mice using AAV8-Transthyretin-Cre (Xbp1Δhep). Xbp1Δhep mice exhibited no liver disease at baseline, but developed acute biochemical and histologic liver injury in response to a dietary challenge with fructose for 4 wk. Fructose-mediated liver injury in Xbp1Δhep mice coincided with heightened IRE1α activity, as demonstrated by cJun phosphorylation and regulated IRE1α -dependent RNA decay (RIDD). Activation of eIF2α was also evident, with associated up-regulation of the pro-apoptotic molecules CHOP, BIM and PUMA. To determine whether the adverse consequences of liver-specific XBP1 deletion were due to XBP1 loss or heightened IRE1α activity, we repeated a fructose challenge in mice with liver-specific deletion of both XBP1 and IRE1α (Xbp1Δhep;IRE1αΔhep). Xbp1Δhep;IRE1αΔhep mice were protected from fructose-mediated liver injury and failed to exhibit any of the signs of ER stress seen in mice lacking XBP1 alone. The protective effect of IRE1α deletion persisted even with long-term exposure to fructose. Xbp1Δhep mice developed liver fibrosis at 16 wk, but Xbp1Δhep;IRE1αΔhep mice did not. Overall, the results indicate that the deleterious effects of hepatocyte-specific XBP1 deletion are due primarily to hyperactivation of IRE1α. They support further exploration of IRE1α as a contributor to acute and chronic liver diseases.
Competing Interest Statement
This work was supported in part by R01 DK068450 (JJM), T32 DK060414 (CCD), K08 DK098270 (ANM), a Pilot/Feasibility Award from the UCSF Liver Center (CCD) and an AASLD Pinnacle Award (CCD). The authors also acknowledge the support of the Cell Biology, Pathology and Immunology Cores of the UCSF Liver Center (P30 DK026743) and the Genome Core of the UCSF Helen Diller Family Comprehensive Cancer Center (P30 CA082103).
Footnotes
Email addresses: Caroline Duwaerts Caroline.Duwaerts{at}ucsf.edu, Kevin Siao Kevin.Siao{at}ucsf.edu, Russell Soon rksoon{at}gmail.com, Chris Her Chris.Her{at}ucsf.edu, Takao Iwawaki iwawaki{at}kanazawa-med.ac.jp, Kenji Kohno kkouno{at}bs.naist.jp, Aras Mattis Aras.Mattis{at}ucsf.edu, Jacquelyn Maher Jacquelyn.Maher{at}ucsf.edu